The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...
The latest trend in treating hair loss may sound familiar — essentially, it’s a repurposed drug first popularized in the ...
Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...
Hims & Hers Health ( HIMS 7.49%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...
FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...
Hims & Hers Health ( HIMS 3.08%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...
Step right up, ladies and gentlemen, and welcome to the hottest new spot in town: The Weight-Loss Casino! Here, you don’t ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...
But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results